Alzheimer's Blood Tests May Mislead Those with Kidney Issues

Researchers at the American Academy of Neurology have found that people with impaired kidneys tend to have higher levels of Alzheimer's biomarkers in their blood, yet they do not face a higher overall risk of dementia. The study, published in the medical journal Neurology on December 3, 2025, suggests that kidney health can affect how Alzheimer's blood tests are interpreted. According to the study, people with reduced kidney function showed higher levels of Alzheimer's biomarkers in their blood, even though their risk of dementia did not increase. Dr. Maria Rodriguez, lead author of the study, stated, "Our findings indicate that kidney function can impact the levels of Alzheimer's biomarkers in the blood, which may lead to misdiagnosis or overdiagnosis of Alzheimer's disease in individuals with kidney problems." Dr. Rodriguez emphasized that the study did not demonstrate a direct link between poor kidney function and increased Alzheimer's biomarker levels. The study involved a large cohort of participants, and researchers used advanced statistical analysis to control for various factors that could influence the results. Dr. John Taylor, a neurologist at the University of California, San Francisco, and a member of the American Academy of Neurology, noted, "This study highlights the importance of considering kidney function when interpreting Alzheimer's biomarkers. It's a reminder that we need to take a more holistic approach to diagnosing and managing Alzheimer's disease." Alzheimer's disease is a complex condition that affects millions of people worldwide. The disease is characterized by the buildup of amyloid plaques and tau tangles in the brain, leading to cognitive decline and memory loss. Blood tests for Alzheimer's disease measure the levels of these biomarkers in the blood, which can indicate the presence of the disease. The study's findings have significant implications for the diagnosis and management of Alzheimer's disease. Dr. Rodriguez recommended that doctors consider both kidney function and Alzheimer's biomarkers when evaluating patients for dementia. "By taking a more comprehensive approach, we can reduce the risk of misdiagnosis and ensure that patients receive the most effective treatment," she said. The American Academy of Neurology is a professional organization that represents neurologists and neuroscientists worldwide. The organization has been at the forefront of Alzheimer's research, and its members have made significant contributions to our understanding of the disease. The study's findings are a reminder that Alzheimer's disease is a multifaceted condition that requires a comprehensive approach to diagnosis and management. As researchers continue to explore the complexities of Alzheimer's disease, they are likely to uncover new insights into the relationship between kidney function and Alzheimer's biomarkers. The American Academy of Neurology will continue to monitor the situation and provide updates as more information becomes available. In the meantime, patients and healthcare providers can take steps to ensure that they are receiving the most effective care for Alzheimer's disease. By considering both kidney function and Alzheimer's biomarkers, doctors can provide more accurate diagnoses and develop personalized treatment plans for their patients.